Published in PLoS One on August 28, 2015
Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical Trial. JAMA Oncol (2016) 1.83
Minimally invasive genomic and transcriptomic profiling of visceral cancers by next-generation sequencing of circulating exosomes. Ann Oncol (2015) 1.48
Integrated digital error suppression for improved detection of circulating tumor DNA. Nat Biotechnol (2016) 1.32
Non-random fragmentation patterns in circulating cell-free DNA reflect epigenetic regulation. BMC Genomics (2015) 0.88
Analysis of Paired Primary-Metastatic Hormone-Receptor Positive Breast Tumors (HRPBC) Uncovers Potential Novel Drivers of Hormonal Resistance. PLoS One (2016) 0.78
Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR(+), HER2(-) advanced breast cancer: results from BOLERO-2. Br J Cancer (2017) 0.77
Application of Circulating Tumor DNA as a Non-Invasive Tool for Monitoring the Progression of Colorectal Cancer. PLoS One (2016) 0.77
Cancer Cell Fusion: Mechanisms Slowly Unravel. Int J Mol Sci (2016) 0.77
Tumor Evolution: Linear, Branching, Neutral or Punctuated? Biochim Biophys Acta (2017) 0.77
Low Input Whole-Exome Sequencing to Determine the Representation of the Tumor Exome in Circulating DNA of Non-Small Cell Lung Cancer Patients. PLoS One (2016) 0.76
Functional oncogene signatures guide rationally designed combination therapies to synergistically induce breast cancer cell death. Oncotarget (2016) 0.75
Use of liquid biopsies to monitor disease progression in a sarcoma patient: a case report. BMC Cancer (2017) 0.75
Are Estrogen Receptor Genomic Aberrations Predictive of Hormone Therapy Response in Breast Cancer? Iran J Cancer Prev (2016) 0.75
Circulating Cell Free Tumor DNA Detection as a Routine Tool forLung Cancer Patient Management. Int J Mol Sci (2017) 0.75
Management of EGFR-mutated non-small-cell lung cancer: practical implications from a clinical and pathology perspective. Curr Oncol (2017) 0.75
Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics (2009) 190.94
The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res (2010) 97.51
A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet (2011) 59.36
Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med (2012) 44.56
Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol (2013) 16.13
Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med (2013) 13.22
Circulating mutant DNA to assess tumor dynamics. Nat Med (2007) 10.33
The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature (2012) 10.17
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature (2012) 8.77
Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med (2014) 8.36
Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer (2011) 7.69
Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature (2013) 7.42
Development of personalized tumor biomarkers using massively parallel sequencing. Sci Transl Med (2010) 6.08
Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci U S A (2005) 5.91
Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med (2012) 5.69
An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med (2014) 4.98
Circulating nucleic acids (CNAs) and cancer--a survey. Biochim Biophys Acta (2006) 4.60
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet (2013) 4.03
Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet (2013) 3.96
Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. Sci Transl Med (2012) 3.92
Cancer genome scanning in plasma: detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing. Clin Chem (2012) 3.35
Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol (2013) 3.34
The implications of clonal genome evolution for cancer medicine. N Engl J Med (2013) 2.78
Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas. Clin Cancer Res (2011) 2.23
Application of a highly sensitive detection system for epidermal growth factor receptor mutations in plasma DNA. J Thorac Oncol (2012) 2.01
Molecular networks that regulate cancer metastasis. Semin Cancer Biol (2012) 1.88
Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer. Sci Transl Med (2014) 1.79
Tumor-specific p53 sequences in blood and peritoneal fluid of women with epithelial ovarian cancer. Am J Obstet Gynecol (2005) 1.72
Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer. Breast Cancer Res Treat (2010) 1.59
Point mutations of the N-ras gene in the blood plasma DNA of patients with myelodysplastic syndrome or acute myelogenous leukaemia. Br J Haematol (1994) 1.55
Multiplex mutation screening by mass spectrometry evaluation of 820 cases from a personalized cancer medicine registry. J Mol Diagn (2011) 1.53
Soluble normal and mutated DNA sequences from single-copy genes in human blood. Cancer Epidemiol Biomarkers Prev (1994) 1.48
Utility of circulating B-RAF DNA mutation in serum for monitoring melanoma patients receiving biochemotherapy. Clin Cancer Res (2007) 1.33
Quantitative and qualitative characterization of plasma DNA identifies primary and recurrent colorectal cancer. Cancer Lett (2008) 1.11